1.Sales and profit
See section β- Tiziana Life Sciences Ltd lost $18.4M in fiscal 2025.
Tiziana Life Sciences Ltd
TLSA Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Download report
3-page PDF: the company, its results and charts with peers.
KIRAβs summary AI analyst
Hi! I read Tiziana Life Sciences Ltdβs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$12.9M in fiscal 2025, β of revenue.
- No open-market insider trades in the last 12 months.
Tiziana Life Sciences Ltd in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$18.4M
No. It lost money last year.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
β
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$0.16 EPS (TTM)
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Tiziana Life Sciences Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
April 30, 2027
Friday Β· in 186 days
- Time
- After the market closes
- Covers
- Period ended Dec 31, 2026
- Source
- Stoqly estimate
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| May 1, 2026 | Period ended Dec 31, 2025 | After the market closes | 20-F β |
| May 6, 2025 | Period ended Dec 31, 2024 | After the market closes | 20-F β |
| May 10, 2024 | Period ended Dec 31, 2023 | After the market closes | 20-F β |
| Apr 26, 2023 | Period ended Dec 31, 2022 | During market hours | 20-F β |
| May 23, 2022 | Period ended Dec 31, 2021 | Time not announced | 20-F β |
| May 17, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
| Jun 17, 2020 | Period ended Dec 31, 2019 | After the market closes | 20-F β |
| Apr 4, 2019 | Period ended Dec 31, 2018 | Before the market opens | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY16
Revenue β
FY17
Revenue β
FY18
Revenue β
FY19
Revenue β
FY20
Revenue β
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY16
Gross β
Operating β
Net β
FCF β
FY17
Gross β
Operating β
Net β
FCF β
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Tiziana Life Sciences Ltd lost $18.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY16
Net income β$9.8M
FY17
Net income β$8.6M
FY18
Net income β$7.9M
FY19
Net income β$9.3M
FY20
Net income β$26.1M
FY21
Net income β$23.4M
FY22
Net income β$15.4M
FY23
Net income β$17.7M
FY24
Net income β$11.9M
FY25
Net income β$18.4M
Diluted EPS
FY16
Diluted EPS β$0.11
FY17
Diluted EPS β$0.09
FY18
Diluted EPS β$0.06
FY19
Diluted EPS β$0.07
FY20
Diluted EPS β$0.16
FY21
Diluted EPS β$0.24
FY22
Diluted EPS β$0.15
FY23
Diluted EPS β$0.17
FY24
Diluted EPS β$0.11
FY25
Diluted EPS β$0.16
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$12.9M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY16
Free cash flow β
FY17
Free cash flow β$7.5M
FY18
Free cash flow β
FY19
Free cash flow β$6.8M
FY20
Free cash flow β$11.3M
FY21
Free cash flow β$21.8M
FY22
Free cash flow β
FY23
Free cash flow β
FY24
Free cash flow β$1.5M
FY25
Free cash flow β$12.9M
Cash from operations vs capital spending
FY16
Cash from operations β
Capital spending $0.0M
FY17
Cash from operations β$7.5M
Capital spending $0.0M
FY18
Cash from operations β$4.6M
Capital spending β
FY19
Cash from operations β$6.8M
Capital spending $0.0M
FY20
Cash from operations β$11.3M
Capital spending $0.0M
FY21
Cash from operations β$21.8M
Capital spending $0.0M
FY22
Cash from operations β$19.6M
Capital spending β
FY23
Cash from operations β$15.7M
Capital spending β
FY24
Cash from operations β$1.5M
Capital spending $0.0M
FY25
Cash from operations β$12.8M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY16
Dividends β
Buybacks β
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.09B
FY17
Diluted shares 0.11B
FY18
Diluted shares 0.13B
FY19
Diluted shares 0.10B
FY20
Diluted shares 0.10B
FY21
Diluted shares 0.10B
FY22
Diluted shares 0.10B
FY23
Diluted shares 0.10B
FY24
Diluted shares 0.11B
FY25
Diluted shares 0.12B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Tiziana Life Sciences Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY16
Cash $5.8M
Debt $0.3M
FY17
Cash $0.1M
Debt $0.3M
FY18
Cash $5.3M
Debt $0.3M
FY19
Cash $0.2M
Debt $0.3M
FY20
Cash $65.8M
Debt $0.3M
FY21
Cash $42.2M
Debt β
FY22
Cash $18.1M
Debt β
FY23
Cash $1.2M
Debt β
FY24
Cash $3.7M
Debt β
FY25
Cash $4.0M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $42.2M | $18.1M | $1.2M | $3.7M | $4.0M |
| Interest coverage | β | β16.7x | β43.7x | β8.9x | β1,174.0x |
| Current ratio | 6.5x | 3.6x | 1.1x | 1.0x | 0.8x |
| Quick ratio | 6.5x | 3.6x | 1.1x | 1.0x | 0.8x |
| Total assets | $48.8M | $26.5M | $12.2M | $11.3M | $11.5M |
| Total liabilities | $7.5M | $6.9M | $6.6M | $7.3M | $11.4M |
| Shareholders' equity | $41.3M | $19.6M | $5.5M | $3.9M | $0.1M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β239.0%
Return on assets β
FY17
Return on capital β
Return on equity β949.5%
Return on assets β347.8%
FY18
Return on capital β11.0%
Return on equity β21.6%
Return on assets β169.0%
FY19
Return on capital β11.2%
Return on equity β12.8%
Return on assets β200.5%
FY20
Return on capital β
Return on equity β39.6%
Return on assets β71.6%
FY21
Return on capital β
Return on equity β45.2%
Return on assets β39.2%
FY22
Return on capital β
Return on equity β50.6%
Return on assets β40.9%
FY23
Return on capital β
Return on equity β140.9%
Return on assets β91.5%
FY24
Return on capital β
Return on equity β250.5%
Return on assets β101.1%
FY25
Return on capital β
Return on equity β924.3%
Return on assets β161.8%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 1 | β / 4 | 4 / 7 | 2 / 7 | 5 / 7 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 |
| Accruals ratio | β | β42.9% | β71.0% | β54.4% | β40.5% | β2.8% | 11.2% | β10.3% | β88.1% | β49.0% |
| Altman Z'' | β | β91.37 | β20.56 | β117.21 | 7.12 | 0.29 | β10.68 | β44.38 | β50.59 | β60.12 |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Research and development | $4.0M | $6.0M | $5.5M | $3.7M | $6.0M | $13.2M | $13.0M | $8.1M | $5.2M | $10.3M |
| Operating income | β$9.9M | β$10.5M | β$9.9M | β$9.9M | β$28.0M | β$27.4M | β$14.6M | β$18.0M | β$15.8M | β$21.1M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.1M | β | β | $0.9M | $0.4M | $1.8M | $0.0M |
| Pretax income | β$9.9M | β$10.5M | β$9.9M | β$10.0M | β$28.3M | β$26.7M | β$15.4M | β$17.2M | β$16.7M | β$18.4M |
| Income tax | β$0.1M | β$1.9M | β$1.9M | β$2.2M | β$2.2M | β$3.2M | β | $0.4M | β$4.9M | β |
| Net income | β$9.8M | β$8.6M | β$7.9M | β$9.3M | β$26.1M | β$23.4M | β$15.4M | β$17.7M | β$11.9M | β$18.4M |
| Diluted EPS | β$0.11 | β$0.09 | β$0.06 | β$0.07 | β$0.16 | β$0.24 | β$0.15 | β$0.17 | β$0.11 | β$0.16 |
| Diluted shares | 0.09B | 0.11B | 0.13B | 0.10B | 0.10B | 0.10B | 0.10B | 0.10B | 0.11B | 0.12B |
| Cash flow | ||||||||||
| Cash from operations | β | β$7.5M | β$4.6M | β$6.8M | β$11.3M | β$21.8M | β$19.6M | β$15.7M | β$1.5M | β$12.8M |
| Capital expenditure | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M |
| Free cash flow | β | β$7.5M | β | β$6.8M | β$11.3M | β$21.8M | β | β | β$1.5M | β$12.9M |
| Stock-based compensation | $1.3M | $0.5M | $0.7M | $1.3M | $0.0M | $5.2M | β$1.4M | $1.7M | $0.9M | $1.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $5.8M | $0.1M | $5.3M | $0.2M | $65.8M | $42.2M | $18.1M | $1.2M | $3.7M | $4.0M |
| Total debt | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | β | β | β | β | β |
| Current assets | β | $2.4M | $6.9M | $1.5M | $70.2M | $48.7M | $24.3M | $7.3M | $7.5M | $8.6M |
| Current liabilities | β | $4.7M | $6.4M | $7.4M | $8.0M | $7.5M | $6.7M | $6.5M | $7.3M | $11.2M |
| Property and equipment, net | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Intangible assets | β | β | β | β | $0.1M | $0.1M | β | β | β | β |
| Total assets | β | $2.5M | $6.9M | $2.4M | $70.7M | $48.8M | $26.5M | $12.2M | $11.3M | $11.5M |
| Total liabilities | β | $4.7M | $6.4M | $7.9M | $8.3M | $7.5M | $6.9M | $6.6M | $7.3M | $11.4M |
| Shareholders' equity | $4.1M | β$2.3M | $75.8M | $69.6M | $62.4M | $41.3M | $19.6M | $5.5M | $3.9M | $0.1M |
| Returns | ||||||||||
| Return on capital | β | β | β11.0% | β11.2% | β | β | β | β | β | β |
| Return on capital employed | β | 460.6% | β1,901.2% | 199.5% | β44.7% | β66.3% | β73.6% | β318.6% | β401.3% | β7,388.8% |
| Return on equity | β239.0% | β949.5% | β21.6% | β12.8% | β39.6% | β45.2% | β50.6% | β140.9% | β250.5% | β924.3% |
| Return on assets | β | β347.8% | β169.0% | β200.5% | β71.6% | β39.2% | β40.9% | β91.5% | β101.1% | β161.8% |
| Return on tangible equity | β239.0% | β | β10.5% | β13.4% | β42.0% | β56.9% | β78.7% | β319.6% | β301.4% | β35,444.2% |
| Growth | ||||||||||
| Share count change | β | 13.7% | 19.9% | β23.7% | 0.0% | 0.6% | 3.7% | 0.9% | 4.1% | 10.9% |
| Financial health | ||||||||||
| Debt / equity | 0.1x | β | 0.0x | 0.0x | 0.0x | β | β | β | β | β |
| Interest coverage | β823.3x | β874.4x | β822.3x | β107.8x | β | β | β16.7x | β43.7x | β8.9x | β1,174.0x |
| Current ratio | β | 0.5x | 1.1x | 0.2x | 8.8x | 6.5x | 3.6x | 1.1x | 1.0x | 0.8x |
| Quick ratio | β | 0.5x | 1.1x | 0.2x | 8.8x | 6.5x | 3.6x | 1.1x | 1.0x | 0.8x |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 4.0 | 2.0 | 5.0 | β | β | β | β | β |
| Altman Z'' | β | β91.4 | β20.6 | β117.2 | 7.1 | 0.3 | β10.7 | β44.4 | β50.6 | β60.1 |
| Accruals ratio | β | β42.9% | β71.0% | β54.4% | β40.5% | β2.8% | 11.2% | β10.3% | β88.1% | β49.0% |
Source: SEC EDGAR XBRL filings (CIK 0001723069). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.